Implementation of a pedagogical skills training programme in postgraduate medical education at Bangabandhu Sheikh Mujib Medical University: Lessons and outcomes
Authors
- Bijoy Kumer Paul
Department of Public Health and Informatics, Bangabandhu Sheikh Mujib Medical University (currently, Bangladesh Medical University), Dhaka, Bangladesh
DOI:
Keywords
Downloads
Correspondence
Publication history
Responsible editor
Reviewers
Funding
Ethical approval
Trial registration number
Copyright
Published by Bangabandhu Sheikh Mujib Medical University (currently, Bangladesh Medical University)
Universities across the globe strive to improve the teaching skills of residents, thereby enriching their educational journey and preparing them for the future. This initiative is not confined to developed nations; even developing countries such as Nigeria are incorporating medical residents into teaching positions to overcome resource limitations [2]. The duration, structure, and subject matter of these teaching programmes, nevertheless, exhibit significant variation [3]. There is unequal distribution of resources and expertise for instruction among residency programmes.
Bangabandhu Sheikh Mujib Medical University, the premier institution in Bangladesh for nurturing skilled healthcare professionals, is dedicated to providing quality medical education, research, and healthcare services. In 2009, the University introduced competency-based medical education for postgraduate residents, featuring a 5-year training programme in clinical faculties (3-4 years for the Basic and Para-clinical Sciences) leads to the degrees MD/MS. This comprehensive programme is divided into two phases, namely Phase-A and Phase-B. Phase-A involves broad-based specialty training, while Phase-B focuses on in-depth, specialty-specific training, ensuring residents' competence and preparing them for specialty qualifications. As part of their Phase-B training, residents of Phase-B participated in a mandatory short course on the 'basics of medical education’ that focused on pedagogical skill training of residents. The Division of Medical Education is responsible for this formal pedagogy skill training for the residents.
Statements | Strongly agree | Agree | Neutral | Disagree | Strongly disagree |
The course enhanced my knowledge of the subject matter | 27 | 65 | 6 | 0 | 2 |
The course contents, modules and structure were relevant and beneficial | 26 | 68 | 3 | 2 | 1 |
Instructors were engaging, supportive, easy to understand, and provide a clear instruction | 46 | 46 | 15 | 0 | 3 |
I feel competent and confident on the on the subject matter at the end of the course | 15 | 50 | 27 | 6 | 2 |
I would recommend this course to others | 47 | 49 | 3 | 1 | 0 |
Statements | Strongly agree | Agree | Neutral | Disagree | Strongly disagree |
The course enhanced my knowledge of the subject matter | 27 | 65 | 6 | 0 | 2 |
The course contents, modules and structure were relevant and beneficial | 26 | 68 | 3 | 2 | 1 |
Instructors were engaging, supportive, easy to understand, and provide a clear instruction | 46 | 46 | 15 | 0 | 3 |
I feel competent and confident on the on the subject matter at the end of the course | 15 | 50 | 27 | 6 | 2 |
I would recommend this course to others | 47 | 49 | 3 | 1 | 0 |
Application | Description | AI techniques used | Benefits | Relevance to drug discovery |
Identification of target | AI analyzes extensive datasets to detect proteins, genes, or pathways affecting disease mechanisms, aiding in identifying promising targets. | Machine learning, data mining | Focuses research on the most promising targets | Target identification is crucial for the success of drug discovery, helping streamline the search for effective treatments. |
Substance testing | AI optimizes drug screening by predicting the most effective compounds, reducing the need for extensive experimental testing. | Predictive models, convolutional neural networks | Reduces experimental workload, accelerates discovery process | AI’s predictive capabilities enhance efficiency by narrowing down the best candidates, saving time and resources. |
Predictive modelling | AI-driven models predict ADMETa properties of drug candidates, helping assess potential effectiveness and safety before experimental validation. | Statistical techniques, machine learning | Expedites and reduces costs of drug development | Predictive modelling reduces failure rates in clinical trials by assessing the safety and efficacy of drugs early in the process. |
Drug repurposing | AI finds new therapeutic uses for approved drugs by uncovering correlations between drugs and diseases. | Data analysis, natural language processing | Accelerates development using existing safety and efficacy data | Drug repurposing is a cost-effective strategy to quickly find new treatments, leveraging existing drugs for new indications. |
aADMET indicates absorption, distribution, metabolism, elimination and toxicity |
Categories | Number (%) |
Sex |
|
Male | 36 (60.0) |
Female | 24 (40.0) |
Age in yearsa | 8.8 (4.2) |
Education |
|
Pre-school | 20 (33.3) |
Elementary school | 24 (40.0) |
Junior high school | 16 (26.7) |
Cancer diagnoses |
|
Acute lymphoblastic leukemia | 33 (55) |
Retinoblastoma | 5 (8.3) |
Acute myeloid leukemia | 4 (6.7) |
Non-Hodgkins lymphoma | 4 (6.7) |
Osteosarcoma | 3 (5) |
Hepatoblastoma | 2 (3.3) |
Lymphoma | 2 (3.3) |
Neuroblastoma | 2 (3.3) |
Medulloblastoma | 1 (1.7) |
Neurofibroma | 1 (1.7) |
Ovarian tumour | 1 (1.7) |
Pancreatic cancer | 1 (1.7) |
Rhabdomyosarcoma | 1 (1.7) |
aMean (standard deviation) |
Categories | Number (%) |
Sex |
|
Male | 36 (60.0) |
Female | 24 (40.0) |
Age in yearsa | 8.8 (4.2) |
Education |
|
Pre-school | 20 (33.3) |
Elementary school | 24 (40.0) |
Junior high school | 16 (26.7) |
Cancer diagnoses |
|
Acute lymphoblastic leukemia | 33 (55) |
Retinoblastoma | 5 (8.3) |
Acute myeloid leukemia | 4 (6.7) |
Non-Hodgkins lymphoma | 4 (6.7) |
Osteosarcoma | 3 (5) |
Hepatoblastoma | 2 (3.3) |
Lymphoma | 2 (3.3) |
Neuroblastoma | 2 (3.3) |
Medulloblastoma | 1 (1.7) |
Neurofibroma | 1 (1.7) |
Ovarian tumour | 1 (1.7) |
Pancreatic cancer | 1 (1.7) |
Rhabdomyosarcoma | 1 (1.7) |
aMean (standard deviation) |